AB0175 C1Q Regulates the TLR7-Mediated Inflammatory Response by Pristane-Primed Macrophages: Implications for Pristane-Induced Lupus (PIL). (10th June 2014)

• Record Type: Journal Article
• Authors: Carlucci, F.; Ishaque, A.; Ling, G.S.; Sandison, A.; Donatien, P.D.; Cook, T.H.; Botto, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 861
• Page End: 861
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.2473
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Intraperitoneal injection of the natural oil pristane induces loss of immune tolerance and development of pristane-induced lupus (PIL) in susceptible mouse strains. PIL is characterised by high titres of autoantibodies, immune-complex glomerulonephritis (GN) and arthritis. The pathogenesis involves induction of apoptosis and a still unknown specific effect of pristane on CD11b + Ly6C h early monocytes which migrate into the peritoneum and produce type I IFN in a TLR7-dependent fashion (1). The role of complement in the pathogenesis of Systemic Lupus Erythematosus (SLE) has been investigated for years with controversial results. Recent data from human studies have shown that C1q may regulate the secretion of type I IFN by plasmacytoid dendritic cells (2, 3). Objectives: Considering the strong association between C1q deficiency and SLE, we tested whether lack of C1q would exacerbate the pristane-induced lupus-like syndrome. Methods: PIL was induced in C1qa –/– animals by intraperitoneal injection and the mice followed up to 9 months post treatment. Autoantibody production was measured by ELISA and kidney and hind paw joint samples were scored by experienced histopathologists. Peripheral blood (PB) and peritoneal lavage (PL) from pristane-injected mice were assessed by flow cytometry. Resident peritoneal macrophages were primed with pristane and cultured overnight in the presence of TLRs ligands. Cytokine production in culture supernatant was detected by ELISA kits. Results: Unexpectedly, the C1qa –/– mice showed a tendency to develop lower titres of circulating anti-snRNP antibodies and less histological evidence of arthritis compared to the wild type controls. No differences were observed in GN severity and survival rate between the complement deficient mice and wild type controls. Consistent with a less severe disease, we found that 2 weeks after the pristane injection the CD11b + Ly6C h monocytes were increased in the PB and decreased in the PL of the C1q-deficient mice, suggesting a defect in the peritoneal recruitment of these cells. Furthermore we observed decreased MIP-1α, MCP-1 and CXCL1/CK production by C1q-deficient pristane-primed resident peritoneal macrophages stimulated in vitro with TLR7 ligand. Conclusions: These novel data indicate that C1q deficient animals are partially resistant to PIL. The protection appears to be related to an impaired chemokine production by pristane-primed peritoneal macrophages. These data suggest that C1q and possibly other complement components are involved in the handling of pristane by phagocytic cells. References: Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L: Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009, 30(9):455-464. Santer DM, Hall BE, George TC, Tangsombatvisit S, Liu CL, Arkwright PD, Elkon KB: C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol2010, 15;185(8):4738-49. Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Ronnblom L, Sturfelt G, Eloranta ML, Bengtsson AA: C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel lonk between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009, 60(10):3081-90. Acknowledgements: We thank the staff of the Biological Services Unit at our institution. This work was supported by the Arthritis Research UK (grant number 19334) and the Wellcome Trust (grant number 088517). Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.2473